Correlation Between Bristol Myers and UroGen Pharma

Can any of the company-specific risk be diversified away by investing in both Bristol Myers and UroGen Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Bristol Myers and UroGen Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Bristol Myers Squibb and UroGen Pharma, you can compare the effects of market volatilities on Bristol Myers and UroGen Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Bristol Myers with a short position of UroGen Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Bristol Myers and UroGen Pharma.

Diversification Opportunities for Bristol Myers and UroGen Pharma

-0.74

Correlation Coefficient

Bristol Myers  UroGen Pharma

Pay attention - limited upside

The 3 months correlation between Bristol and UroGen is -0.74. Overlapping area represents the amount of risk that can be diversified away by holding Bristol Myers Squibb and UroGen Pharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on UroGen Pharma and Bristol Myers is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Bristol Myers Squibb are associated (or correlated) with UroGen Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of UroGen Pharma has no effect on the direction of Bristol Myers i.e., Bristol Myers and UroGen Pharma go up and down completely randomly.

Pair Corralation between Bristol Myers and UroGen Pharma

Considering the 90-day investment horizon Bristol Myers Squibb is expected to generate 0.67 times more return on investment than UroGen Pharma. However, Bristol Myers Squibb is 1.49 times less risky than UroGen Pharma. It trades about 0.15 of its potential returns per unit of risk. UroGen Pharma is currently generating about -0.03 per unit of risk. If you would invest  4,940  in Bristol Myers Squibb on August 30, 2024 and sell it today you would earn a total of  987.00  from holding Bristol Myers Squibb or generate 19.98% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	98.44%
Values	Daily Returns

Bristol Myers Squibb  vs.  UroGen Pharma

Bristol Myers Squibb

Risk-Adjusted Performance

12 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Bristol Myers Squibb are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain primary indicators, Bristol Myers showed solid returns over the last few months and may actually be approaching a breakup point.

UroGen Pharma

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days UroGen Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unfluctuating performance, the Stock's technical and fundamental indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors.

Pair Trading with Bristol Myers and UroGen Pharma

The main advantage of trading using opposite Bristol Myers and UroGen Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Bristol Myers position performs unexpectedly, UroGen Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will offset losses from the drop in UroGen Pharma's long position.

The idea behind Bristol Myers Squibb and UroGen Pharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.